Sutro Biopharma, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by Sutro Biopharma, Inc. on June 20, 2025. The report addresses a regulatory notice received from The NASDAQ Stock Market, LLC regarding the continued listing of the Company's common stock (Trading Symbol: STRO) on The NASDAQ Global Market.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on compliance with listing standards rather than financial performance metrics.
Material Changes
The material event reported is the receipt of a notice of non-compliance with NASDAQ Listing Rule 5450(a)(1), which requires a minimum bid price of $1.00 per share. The Company's stock has traded below this threshold, triggering a compliance period.
Outlook, Risks, and Management Commentary
- Compliance Period: The Company has 180 calendar days, until December 17, 2025, to regain compliance.
- Requirements: To comply, the closing bid price must meet or exceed $1.00 per share for a minimum of ten consecutive business days within the 180-day window.
- Contingency Plans: If the Company fails to comply by the deadline, it may elect to transfer to The NASDAQ Capital Market to access a second 180-day compliance period, subject to meeting other listing standards.
- Management Action: The Company intends to monitor the stock price and plans to implement a reverse stock split if necessary to cure the deficiency.
- Risk of Delisting: Failure to regain compliance within the allotted periods, including any extensions, will result in delisting. The Company retains the right to appeal such a determination to a NASDAQ Listing Qualifications Panel.
Investor Verification Checklist
- Verify the current closing bid price of STRO to assess the gap to the $1.00 threshold.
- Monitor the Company's announcements regarding the potential implementation of a reverse stock split.
- Review the Company's market value of publicly held shares to determine eligibility for a transfer to The NASDAQ Capital Market if the initial cure period fails.
- Track the stock price performance over the next 180 days to confirm if the ten consecutive business day requirement is met.